Trend, exactly. I actually do not see that as a bad thing. Lets face it, Regabatin, Rexista, Podras alone is a great start. They could sell of the generics get enough cash to get them through next year and Rexista approval. Say 15 million for all the generics. Then start licensing out Podras and then they can start working on the so called other 20 NDA's !
The one thing that has been holding back the company has never been the technology. I for one have been here since 2012 because of the technology. NOT because of Odidi. The only reason I am STILL here is because of him and his unwillingness to ink deals.
The only downside I see here, is if a new player comes in and takes the next 25% and then we have no clear winner. But I am betting Boyd won't let his investment go south.
I'm ready!